Bill would enhance FDA's antibiotics reporting

ADVERTISEMENT
"While decades of science clearly show that these practices breed drug-resistant bacteria that can infect us, we need to know more about the scope of the problem."

The Antimicrobial Data Collection Act is a boon to health advocates who say the federal government should do more to cut the use of antibiotics in livestock.

The practice contributes to drug-resistant disease, which clinicians consider a looming public health crisis.

Sens. Kirsten GillibrandKirsten Elizabeth GillibrandOvernight Health Care — Sponsored by PCMA — Trump hits federally funded clinics with new abortion restrictions Dem senators ask drug companies to list prices in ads Gillibrand to publish children's book about suffragists MORE (D-N.Y.), Dianne FeinsteinDianne Emiel FeinsteinCongress — when considering women’s health, don’t forget about lung cancer Overnight Energy: Pruitt taps man behind 'lock her up' chant for EPA office | Watchdog to review EPA email policies | Three Republicans join climate caucus Man who coined 'lock her up' chant to lead EPA's Pacific Southwest office MORE (D-Calif.) and Susan CollinsSusan Margaret CollinsDem rep to launch discharge petition to force net neutrality vote in House Hillicon Valley: Senate votes to save net neutrality | Senate panel breaks with House, says Russia favored Trump in 2016 | Latest from Cambridge Analytica whistleblower | Lawmakers push back on helping Chinese tech giant Overnight Health Care — Sponsored by PCMA — ObamaCare premium wars are back MORE (R-Maine) introduced the bill on Wednesday.

It would require the FDA to establish a pilot program to find new data sources on antibiotic use in livestock, in addition to setting new standards for how federal officials publish that data.

The bill would also set a deadline for the FDA to finalize policies meant to curb the use of antibiotics in agriculture.

"Our bill would not create any new reporting requirements for drug companies, feed mills, or farmers," said Collins in a statement.

"It would only require the FDA to provide more transparency in reporting the antimicrobial data which is already being reported to it."